iBio, Inc. (IBIO): Price and Financial Metrics

iBio, Inc. (IBIO)

Today's Latest Price: $1.76 USD

0.30 (20.55%)

Updated Jan 22 6:40pm

Add IBIO to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 484 in Biotech

See all "A" rated Strong Buy stocks

IBIO Stock Summary

  • With a price/sales ratio of 165.21, iBio Inc has a higher such ratio than 97.29% of stocks in our set.
  • The volatility of iBio Inc's share price is greater than that of 94.05% US stocks with at least 200 days of trading history.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for IBIO comes in at -32.75% -- higher than that of just 8.15% of stocks in our set.
  • Stocks that are quantitatively similar to IBIO, based on their financial statements, market capitalization, and price volatility, are LODE, BNGO, RWLK, ZKIN, and CBT.
  • IBIO's SEC filings can be seen here. And to visit iBio Inc's official web site, go to www.ibioinc.com.

IBIO Stock Price Chart Interactive Chart >

Price chart for IBIO

IBIO Price/Volume Stats

Current price $1.76 52-week high $7.45
Prev. close $1.46 52-week low $0.23
Day low $1.63 Volume 51,274,598
Day high $1.84 Avg. volume 20,081,742
50-day MA $1.40 Dividend yield N/A
200-day MA $1.93 Market Cap 320.51M

iBio, Inc. (IBIO) Company Bio

iBio, Inc. is a biotechnology company, which engages in the development and manufacture of biotherapeutics. Its pipeline include idiopathic pulmonary fibrosis, systemic sclerosis, and scleroderma. It operates through the iBio, Inc. and iBio CDMO business segments. The company was founded on April 15, 1993 and is headquartered in New York, NY.

IBIO Latest News Stream

Event/Time News Detail
Loading, please wait...

IBIO Latest Social Stream

Loading social stream, please wait...

View Full IBIO Social Stream

Latest IBIO News From Around the Web

Below are the latest news stories about iBio Inc that investors may wish to consider to help them evaluate IBIO as an investment opportunity.

iBio surges after Cantor Fitzgerald initiates coverage with overweight rating

iBio (IBIO) has risen more than fourfold in value over the past six-month period amid COVID-19 vaccine hopes. That has not discouraged Cantor Fitzgerald to initiate the stock’s coverage with an overweight rating with a price target of $3, more than double the previous close. The shares have added ~13.7% so...

Seeking Alpha | January 22, 2021

Why iBio Stock Soared Today

Cantor Fitzgerald analyst Kristen Kluska placed an overweight rating on iBio's stock after the market close on Thursday. Kluska says iBio's stock is largely under the radar of most investors and that its current price fails to reflect the company's position as a leader in plant-based biologics manufacturing.

Yahoo | January 22, 2021

iBio Appoints Dr. Martin B. Brenner as Chief Scientific Officer

BRYAN, Texas, Dec. 28, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today announced the appointment of Martin B. Brenner, DVM, Ph.D., as its Chief Scientific Officer (“CSO”), effective January 18, 2020. “We are thrilled to have Dr. Brenner join our team,” said Tom Isett, Chairman & CEO of iBio. “Given his prior experience leading organizations with novel protein expression platforms to build proprietary product pipelines, Dr. Brenner should be uniquely suited to assist iBio with a similar transformation. Notably, he also brings a track-record of effective new target search and evaluation, as well as establishing productive collaborations.”Dr. Brenner has a strong history of success hea...

Yahoo | December 28, 2020

iBio Announces Closing of its Public Offering of Common Stock

BRYAN, Texas, Dec. 10, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract…

GlobeNewswire | December 10, 2020

Why iBio, Sutro And Cantel Medical Are Moving Today

iBio (NYSE: IBIO ) shares … Full story available on Benzinga.com

Benzinga | December 8, 2020

Read More 'IBIO' Stories Here

IBIO Price Returns

1-mo N/A
3-mo -8.33%
6-mo -59.63%
1-year 530.82%
3-year -1.68%
5-year -67.41%
YTD 67.62%
2020 321.69%
2019 -66.80%
2018 -57.63%
2017 -55.75%
2016 -28.57%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.8277 seconds.